Rheumatoid Arthritis Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Rheumatoid Arthritis Drugs Market Report is Segmented by Type of Molecule (Pharmaceuticals and Biopharmaceuticals), Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs (DMARDs), Corticosteroids, Analgesics, and Other Drug Classes), Sales Channel (Prescription and Over-The-Counter (OTC)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Market Sizes and Forecasts in Terms of Value (USD) for the Above Segments.

Rheumatoid Arthritis Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Rheumatoid Arthritis Drugs Market Size

Rheumatoid Arthritis Drugs Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 59.88 Billion
Market Size (2030) USD 79.67 Billion
CAGR (2025 - 2030) 5.88 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Rheumatoid Arthritis Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Rheumatoid Arthritis Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Rheumatoid Arthritis Drugs Market Analysis

The Rheumatoid Arthritis Drugs Market size is estimated at USD 59.88 billion in 2025, and is expected to reach USD 79.67 billion by 2030, at a CAGR of 5.88% during the forecast period (2025-2030).

The key factors propelling the growth of the rheumatoid arthritis drugs market are the launch of new biosimilars, the rising prevalence of arthritis across the world, and the acceptance of biopharmaceuticals. Various factors, such as increasing age and lifestyle changes, are expected to raise the risk for rheumatoid arthritis, which is expected to drive the market growth over the study period. For instance, according to the data published by the National Center for Health Statistics in February 2024, the prevalence of arthritis was found to be directly proportional to the rising age across the world, rising from 3.6% in adults aged 18–34 to 53.9% in individuals aged 75 and older. This scenario may lead to increased adoption of therapies for rheumatoid arthritis treatment and thus drive the market’s growth.

The rising burden of rheumatoid arthritis in various age groups is expected to increase the need for its drug treatment, boosting the market growth. For instance, as per the data published by Statistique Canada in November 2023, the number of people aged 12 years and over in Canada with arthritis was reported to be 6.28 million in 2022, compared to 6.08 million in the previous year. Hence, the growing prevalence of arthritis among the population may increase the demand for arthritis drugs, which may drive the market growth over the forecast period.

Additionally, rising launches of biosimilars for treating rheumatoid arthritis may also contribute to market growth. For instance, in October 2023, Pfizer Inc. secured an interchangeable biosimilar designation for ABRILADA (adalimumab-afzb) from the US Food and Drug Administration (FDA). This interchangeable designation encompasses all approved indications of ABRILADA, which include specific patients with rheumatoid arthritis (RA). Similarly, in July 2023, Coherus BioSciences Inc. launched YUSIMRY (adalimumab-aqvh) for commercial sale in the United States. It is one of the biosimilars to Humira in treating rheumatoid arthritis. Hence, affordable rheumatoid arthritis treatments are anticipated to witness demand in the coming years.

Thus, owing to the abovementioned factors, such as the rising burden of rheumatoid arthritis and new product launches, the market is expected to grow over the forecast period. However, alternative treatment options and the expiration of the patents of branded drugs may hinder the market's growth during the forecast period.

Rheumatoid Arthritis Drugs Industry Overview

The rheumatoid arthritis drugs market is semi-consolidated, and key players are manufacturing most rheumatoid arthritis drug products. The market leaders in this industry have established their position in the market. These manufacturers have a wide product range to offer and an extensive distribution system across the world. Additionally, emerging markets in Asia-Pacific are witnessing the entry of small players. Some major players in this market include AbbVie Inc., Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, and Eli Lilly and Company.

Rheumatoid Arthritis Drugs Market Leaders

  1. AbbVie Inc.

  2. Amgen Inc.

  3. Bayer AG

  4. Boehringer Ingelheim GmbH

  5. Bristol-Myers Squibb Company

  6. *Disclaimer: Major Players sorted in no particular order
Rheumatoid Arthritis Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Rheumatoid Arthritis Drugs Market News

  • June 2024: Celltrion unveiled its positive phase III results for CT-P47, a biosimilar targeting RoActemra, in patients grappling with moderate-to-severe rheumatoid arthritis (RA).
  • April 2024: Kiniksa Pharmaceutical Ltd unveiled findings from Cohort 4 of its Phase 2 clinical trial for abiprubart, targeting rheumatoid arthritis. Abiprubart, an investigational humanized anti-CD40 monoclonal antibody, aims to block the interaction between CD40 and its ligand, CD154.

Rheumatoid Arthritis Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Preference Toward Development of Biologics and Biosimilars
    • 4.2.2 Rising Burden of Arthritis
  • 4.3 Market Restraints
    • 4.3.1 Patent Expiration of Blockbuster Drugs
    • 4.3.2 Alternative Treatment Options
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Type of Molecule
    • 5.1.1 Pharmaceuticals
    • 5.1.2 Biopharmaceuticals
  • 5.2 By Drug Class
    • 5.2.1 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    • 5.2.2 Disease-modifying Antirheumatic Drugs (DMARDs)
    • 5.2.3 Corticosteroids
    • 5.2.4 Analgesics
    • 5.2.5 Other Drug Classes
  • 5.3 By Sales Channel
    • 5.3.1 Prescription
    • 5.3.2 Over-the-Counter (OTC)
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 Bayer AG
    • 6.1.4 Boehringer Ingelheim GmbH
    • 6.1.5 Bristol-Myers Squibb Company
    • 6.1.6 Celgene Corporation
    • 6.1.7 F. Hoffmann-La Roche AG
    • 6.1.8 Johnson & Johnson
    • 6.1.9 Merck & Co. Inc.
    • 6.1.10 Novartis AG
    • 6.1.11 Lupin Limited
    • 6.1.12 Alkem Laboratories
    • 6.1.13 Regeneron Pharmaceuticals
    • 6.1.14 Eli Lilly and Company
    • 6.1.15 Pfizer Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Rheumatoid Arthritis Drugs Industry Segmentation

Rheumatoid arthritis is an autoimmune disorder that causes pain and inflammation in the body's joints. It primarily affects the joints of the hands, wrists, elbows, knees, and ankles. It also affects the cardiac and respiratory systems and is a systemic disease. It thus exhibits symptoms of swelling, redness, and warmth in the affected areas. The drugs to treat rheumatoid arthritis include NSAIDs, corticosteroids, DMARDs, biologics, and analgesics, which help reduce inflammation, suppress the immune system, and relieve pain.

The rheumatoid arthritis drugs market is segmented by type of molecule, drug class, sales channel, and geography. By type of molecule, the market is segmented into pharmaceuticals and biopharmaceuticals. By drug class, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), corticosteroids, analgesics, and other drug classes. By sales channel, the market is segmented into prescription and over-the-counter (OTC). By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across significant global regions. The report offers market sizes and forecasts in terms of value (USD) for the above segments.

By Type of Molecule Pharmaceuticals
Biopharmaceuticals
By Drug Class Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Disease-modifying Antirheumatic Drugs (DMARDs)
Corticosteroids
Analgesics
Other Drug Classes
By Sales Channel Prescription
Over-the-Counter (OTC)
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Rheumatoid Arthritis Drugs Market Research Faqs

How big is the Rheumatoid Arthritis Drugs Market?

The Rheumatoid Arthritis Drugs Market size is expected to reach USD 59.88 billion in 2025 and grow at a CAGR of 5.88% to reach USD 79.67 billion by 2030.

What is the current Rheumatoid Arthritis Drugs Market size?

In 2025, the Rheumatoid Arthritis Drugs Market size is expected to reach USD 59.88 billion.

Who are the key players in Rheumatoid Arthritis Drugs Market?

AbbVie Inc., Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH and Bristol-Myers Squibb Company are the major companies operating in the Rheumatoid Arthritis Drugs Market.

Which is the fastest growing region in Rheumatoid Arthritis Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Rheumatoid Arthritis Drugs Market?

In 2025, the North America accounts for the largest market share in Rheumatoid Arthritis Drugs Market.

What years does this Rheumatoid Arthritis Drugs Market cover, and what was the market size in 2024?

In 2024, the Rheumatoid Arthritis Drugs Market size was estimated at USD 56.36 billion. The report covers the Rheumatoid Arthritis Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Rheumatoid Arthritis Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Rheumatoid Arthritis Drugs Industry Report

Statistics for the 2025 Rheumatoid Arthritis Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Rheumatoid Arthritis Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.